You are here

Article Text

Article menu

Download PDFPDF

Research Article
Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy.
  1. A Kataoka,
  2. H Imai,
  3. S Inayoshi,
  4. T Tsuda
  1. Third Department of Internal Medicine, Oita Medical University, Japan.

    Abstract

    The efficacy of intermittent high-dose vitamin C therapy was evaluated in seven patients with HTLV-I-associated myelopathy (HAM). All HAM patients responded well to this therapy without serious side effects. Grade of disability score improved at 9.7 (SD 5.8) months after the therapy from 7.1 (3.3) to 3.6 (2.0) (p < 0.01). Serum immunosuppressive acidic protein was elevated before and decreased after the therapy from 747 (316) to 398 (86) micrograms/ml (p < 0.05), suggesting favourable immunomodulatory action of vitamin C therapy in HAM patients.

    https://doi.org/10.1136/jnnp.56.11.1213

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.